147 related articles for article (PubMed ID: 1854505)
1. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors.
Eriksson B; Oberg K
Acta Oncol; 1991; 30(4):477-83. PubMed ID: 1854505
[TBL] [Abstract][Full Text] [Related]
2. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
3. The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours.
Stridsberg M
Ups J Med Sci; 1995; 100(3):169-99. PubMed ID: 8808182
[No Abstract] [Full Text] [Related]
4. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.
Ardill JE; Erikkson B
Endocr Relat Cancer; 2003 Dec; 10(4):459-62. PubMed ID: 14713258
[TBL] [Abstract][Full Text] [Related]
5. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours.
Eriksson B; Arnberg H; Oberg K; Hellman U; Lundqvist G; Wernstedt C; Wilander E
Acta Endocrinol (Copenh); 1990 Feb; 122(2):145-55. PubMed ID: 2316306
[TBL] [Abstract][Full Text] [Related]
6. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
[TBL] [Abstract][Full Text] [Related]
7. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
8. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract.
Grem J
Curr Opin Oncol; 1997 Jul; 9(4):380-7. PubMed ID: 9251889
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
13. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
[TBL] [Abstract][Full Text] [Related]
14. Approach to hepatic involvement by endocrine tumors of the gastrointestinal tract.
Stockmann F; Creutzfeldt W
Semin Liver Dis; 1988 Aug; 8(3):254-62. PubMed ID: 2906761
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
16. Detection of tumor associated antigen, PA8-15, in sera from pancreatic and gastrointestinal carcinoma patients.
Arai M; Sakamoto K; Otsuka H; Yokoyama Y; Akagi M
Jpn J Clin Oncol; 1990 Jun; 20(2):145-53. PubMed ID: 2370693
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
18. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
19. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
20. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
